QURE INVESTOR ALERT: uniQure Faces Securities Class Action Over AMT-130 Clinical Trial Design – Hagens Berman

Core Viewpoint - Hagens Berman is reminding investors of the approaching Lead Plaintiff Deadline in the litigation against uniQure N.V. regarding misleading statements about its gene therapy candidate AMT-130 [1][3] Company Overview - uniQure N.V. is focused on developing treatments for rare and devastating diseases, with its leading drug candidate being AMT-130, a gene therapy aimed at slowing Huntington's disease progression [3][4] Legal Allegations - The lawsuit claims that uniQure and its executives made inaccurate statements about the FDA's acceptance of a pivotal study design for AMT-130, which did not include a traditional placebo control [2][4] - Allegations include misrepresentation of the FDA's stance on the adequacy of data from Phase I/II studies for a Biologics License Application (BLA) submission [4][6] Impact of Allegations - The truth about the regulatory path for AMT-130 was allegedly revealed on November 3, 2025, leading to a more than 49% drop in uniQure's share price [4][5] - The company stated that the timing for the BLA submission is now unclear and plans to engage urgently with the FDA for a path forward [4][6] Investigation Details - Hagens Berman is investigating the discrepancies between what uniQure communicated to investors and the details from recent FDA meeting minutes [5] - The firm is encouraging investors who suffered losses during the Class Period (Sept. 24, 2025 – Oct. 31, 2025) to come forward [3][5]